All of the above points mean that even for oncogene mutations linked to decreased infiltrate, like FGFR3 in bladder cancer, there is no assurance that inhibition of the oncogene's signaling pathway will alter tumor immune dynamics. Here, FGFR3 is linked to neoplasm.